ABVC BioPharma Plans to Expand Investment in U.S. for Production Facilities and Products for Unmet Medical NeedsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC and BioLite Japan Implement Strategy to Advance Japan's Biotech Innovation Into Global MarketsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC and BioLite Japan Implement Strategy to Advance Japan's Biotech Innovation Into Global MarketsFREMONT, CA - February 26, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (
NASDAQABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, announces a new strategy with its joint venture partner, BioLite Japan. The parties aim to accelerate the growth of Japan's biotechnology industry by facilitating access to Taiwan’s capital market and leveraging cutting-edge AI resources for advanced development.
AiBtl BioPharma Strengthens Partnership With ABVC BioPharma, Paying $150,000 in Licensing FeesLicensing Fees From AiBtl and Strategic Partners Now Total $696,000, Bolstering Confidence in AiBtl’s Plans
ABVC BioPharma Announces Potential $7M Cash Licensing Income from Existing Agreements in 2025FREEMONT, CALIFORNIA - February 20, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (
NASDAQABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, central nervous system (CNS), and oncology/hematology, today announced its expectation to receive $7M in cash licensing income in 2025, stemming from existing global licensing agreements the Company and one of its subsidiaries signed in 2023. The company is also highlighting significant progress in its botanical drug development pipeline and its plans to leverage land assets for future development.
ABVC BioPharma Announces Potential $7M Cash Licensing Income from Existing Agreements in 2025Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Positive Market Response in Asia Fuels Potential Revenue Growth for ABVC and BioKey, Marching Into Global Dietary Supplements Market of USD 75.35 BillionFREMONT, CA - February 12, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (
NASDAQABVC), a clinical-stage biopharmaceutical company focusing on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, today announced its participation in BioLive’s (formerly known as TT Life) Health Talk Event, marking a significant milestone in the company’s growth and its role in advancing innovative healthcare solutions by penetrating a new market in Asia. The event showcased BioKey’s Maitake BLEX 404 Dietary Supplement, a groundbreaking therapy created for cancer combination treatment and to enhance immunity, in an effort to help improve the quality of life for cancer patients.
ABVC BioPharma and AiBtl BioPharma's Worldwide Business Development Team Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC BioPharma s ADHD and MDD Drug Polygala Tenuifolia a Natural Wonder With Potential of Transforming Mental Health Treatment of More Than 30 Billion MarketFREMONT, CA - January 15, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (
NASDAQABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, is proud to announce the advancements in its innovative treatments for Major Depressive Disorder (MDD) and Attention-Deficit/Hyperactivity Disorder (ADHD), highlighting the promising results achieved through rigorous clinical research and development.
AiBtl BioPharma Strengthens Partnership With ABVC BioPharma, Paying $150,000 in Licensing FeesSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC BioPharma, Inc. Granted Additional 180-Day Grace Period to Regain Compliance With Nasdaq Bid Price RequirementSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC BioPharma, Inc. Granted Additional 180-Day Grace Period to Regain Compliance With Nasdaq Bid Price RequirementFREMONT, CA - January 13, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (
NASDAQABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, is pleased to announce that Nasdaq has granted the Company an additional 180-day grace period, until July 7, 2025, to regain compliance with the Nasdaq Capital Market’s minimum $1.0 bid price per share requirement.
ABVC BioPharma and ForSeeCon: An Update on Alliance's Ophthalmology-Related ProductsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic AchievementsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
